Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company developing molecular glue degraders (MGDs), small molecule drugs that selectively degrade disease-relevant proteins by leveraging the body's natural protein destruction mechanisms via E3 ligases such as cereblon. Key pipeline candidates include MRT-2359 (GSPT1-directed), MRT-6160 (VAV1-directed, out-licensed to Novartis), and MRT-8102 (NEK7-directed). The company uses its proprietary QuEEN discovery engine to identify and rationally design MGD product candidates.
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001193125-26-109360 | EDGAR | 119K words |
| 2025-03-20 | 2024-12-31 | 0000950170-25-042344 | EDGAR | 123K words |
| 2024-03-14 | 2023-12-31 | 0000950170-24-031150 | EDGAR | 104K words |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008440 | EDGAR | 97K words |
| 2022-03-29 | 2021-12-31 | 0000950170-22-004927 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-336711 | EDGAR | 26K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-268045 | EDGAR | 26K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104550 | EDGAR | 26K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066372 | EDGAR | 20K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-122780 | EDGAR | 23K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093296 | EDGAR | 22K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056288 | EDGAR | 18K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061995 | EDGAR | 22K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040959 | EDGAR | 20K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021201 | EDGAR | 18K words |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024447 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016844 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-08 | 0001193125-26-384360 | EDGAR | 2K words |
| 2026-08-06 | 0001193125-26-336681 | EDGAR | 4K words |
| 2026-03-17 | 0001193125-26-109353 | EDGAR | 5K words |
| 2026-02-10 | 0001193125-26-044616 | EDGAR | 1K words |
| 2026-01-09 | 0001193125-26-009005 | EDGAR | 1K words |
| 2026-01-07 | 0001193125-26-006341 | EDGAR | 1K words |
| 2026-01-07 | 0001193125-26-005420 | EDGAR | 2K words |
| 2025-12-16 | 0001193125-25-319981 | EDGAR | 2K words |
| 2025-11-06 | 0001193125-25-268042 | EDGAR | 4K words |
| 2025-09-15 | 0001193125-25-202760 | EDGAR | 1K words |
83 total filings indexed. 56 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001826457 |
| Ticker | GLUE |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.monterosatx.com |
| Listed | 2021-06-24 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GLUE (~200 tokens, structured JSON with cryptographic provenance)